An interventional study of Linear Asymmetric rTMS System in Treatment Resistant Depression, sponsored by NeuroQore Inc.. Withdrawn at 1 site in Canada. Open to participants aged 15 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by NeuroQore Inc. · Not applicable, Interventional, and Treatment
Due to a strategic decision by the sponsor, the study has been relocated to a different site, necessitating the withdrawal of this specific registration.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Depressive Disorder, Treatment-Resistant with a site in Canada — 29 open to participants now, 36 under way, 7 of them phase 3. Depressive Disorder, Treatment-Resistant · Canada.
Among the 76 studies in Depressive Disorder, Treatment-Resistant with a site in Canada, this one is the 68th largest by enrollment of the 70 interventional ones that give a count, is one of 11 that started in 2025, is one of 33 with no phase, and was the 23rd registered.
450 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 148 are open to participants now.
Browse Depressive Disorder, Treatment-Resistant studies →29 of the 76 studies in Depressive Disorder, Treatment-Resistant with a site in Canada are open now. Recruiting first, the newest first:
The Royal's Institute of Mental Health Research · Sites in Canada
Ages 18–65
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18–65
Joshua Rosenblat · Sites in Canada
Ages 18–70
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–70
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 115 Depressive Disorder, Treatment-Resistant studies recruiting now, 27 (23%) set no upper age limit and 76 (66%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.
This study: 15 Years to 17 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 18 · Phase 3 12 · Phase 4 7
First in 2002; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 50 across the 70 interventional studies, 63 across the 6 observational. Of the 33 that completed or were terminated, 8 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 76 have an industry lead sponsor. The 10 most frequent:
NeuroQore Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.
NeuroQore Inc. has 1 study filed under Depressive Disorder, Treatment-Resistant — fewer than ten, so there is no comparison to draw.
12 of the studies in Depressive Disorder, Treatment-Resistant with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07262008Phase 3Women's College HospitalSustained Mood Improvement With Laughing Gas Exposure | 2027-02-01 |
| NCT05570344University of AlbertarTMS With and Without Text4Support for the Treatment of Resistant Depression. | 2026-12-31 |
| NCT06163625Unity Health TorontoThe Impact of Working Memory and Reward Markers on DLPFC Activity in Treatment-resistant Depression | 2026-12-31 |
| NCT06731621Centre for Addiction and Mental HealthPsilocybin for Treatment-Resistant Depression in Autism | 2027-01 |
| NCT07212465Rotman Research Institute at BaycrestAccelerated Neuromodulation of Anterior Cingulate Cortex for Depression | 2027-01-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 76 studies in Depressive Disorder, Treatment-Resistant with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a pilot interventional study to investigate the acceptability, tolerability, and side effect profile for varying numbers of treatment sessions/day of a new rTMS treatment in adolescents with treatment-resistant depression (TRD). Conventional rTMS has been limited to sinusoidal biphasic electromagnetic pulses. In contrast, the First Dawn rTMS system by NeuroQore can sustain a repetitive linear asymmetric pulse. In addition, identification of rTMS treatment sites in adolescents with TRD most often relies on anatomic landmarks, but the First Dawn rTMS system utilizes personal fMRI data in a novel algorithm to determine where to apply the rTMS in each patient.
Based on adult data in healthy volunteers and patients with TRD, the investigators propose that the First Dawn rTMS system will be acceptable and well-tolerated by adolescents and will have minimal side effects. Please see https://clinicaltrials.gov/ct2/show/NCT02667041 for details on the completed pilot study in adults.
The investigators aim to investigate acceptability, tolerability, and side effects in groups of patients receiving treatment in numbers of sessions/day that are gradually accelerated over the course of the study. Results will be used to inform the development of a randomized controlled trial.
The 18 patients will be placed into 6 sub-groups sequentially as they are enrolled. All patients will receive a maximum of 30,000 pulses in their treatment course, as tolerated. The first group will receive daily sessions, similar to standard rTMS treatment. Each of the remaining groups will be set to receive more frequent sessions/day in decreasing numbers of days on a graduated schedule while holding the total number of pulses for each patient's treatment course at 30,000 pulses. in addition, the investigators will recruit one healthy volunteer to test fMRI server data transfer and analysis. This healthy volunteer will not receive rTMS.
Primary Objectives
The primary objectives of this study are to assess: 1) the feasibility of enrollment (number of patients who enroll divided by the number of patients approached), 2) study retention (number of patients completing the study divided by the number enrolled), and 3) AE/SE profile of the treatment at each protocol level and 4) patient experience in the study across the sample and within the sub-groups.
Secondary Objectives
The secondary objectives of this study are to: 1) evaluate daily changes in symptoms of depression and mental status; 2) evaluate fMRI changes in the LDLPFC after treatment; 3) evaluate post-treatment and 3-month changes in depression symptoms, global function, mental status, verbal memory.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Meets criteria for TRD:
Exclusion:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: First Dawn rTMS System used in 18 patients divided into groups of 3. Each group will receive a different and gradually increasing frequency of treatment sessions/day (1-10) over a decreasing number of days (10-1). The total number of pulses for all levels will be 30,000. The use of each level will be dependent on tolerability and safety of the previous lower level, i.e., if one level is not tolerated well by a group, progression to the next level will not occur.
Device: Linear Asymmetric rTMS System
Linear Asymmetric rTMS System
Patient Enrollment Rate
Number of patients who give consent divided by the number who are approached.
Time frame: Through study completion, an average of 10 months
Patient Completion Rate
Number of patients who complete the study divided by the number of patients who enroll in the study.
Time frame: Through study completion, an average of 10 months
Side Effects Profile
Measured with the rTMS Side Effect Questionnaire
Time frame: Through study completion, an average of 10 months
Patient Experience
Measured with the Multi-Care Institute for Research and Innovation Research Participant Satisfaction Questionnaire
Time frame: Through study completion, an average of 10 months
Change in self-reported MDD symptoms
Measured with the Child Depression Inventory-2.(CDI-2)
Time frame: Change from baseline score to score at 3 months
Change in clinician-rated MDD symptoms
Measured with the Child Depression Rating Scale-Revised (CDRS-R)
Time frame: Change from baseline score to score at 3 months
Change in function
Measured with the Children's Global Assessment Scale (C-GAS)
Time frame: Change from baseline score to score at 3 months
Change in mental status
Measured with the Mini-Mental State Examination (MMSE)
Time frame: Change from baseline score to score at 3 months
Change in short-term verbal memory
Measured with the Hopkins Verbal Learning Test-Revised (HLVT-R)
Time frame: Change from baseline score to score at 3 months
Plan to share: No — clintrials.gov
No publications or documents are linked to this record.
Start is estimated for May 2025; primary completion for Oct 2028, 41 months later.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: start Mar 2022 → May 2025, primary completion Oct 2022 → Oct 2028 and completion Dec 2022 → Dec 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Due to a strategic decision by the sponsor, the study has been relocated to a different site, necessitating the withdrawal of this specific registration.
Due to a strategic decision by the sponsor, the study has been relocated to a different site, necessitating the withdrawal of this specific registration.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Depressive Disorder, Treatment-Resistant →